Markets are forward looking, in the meantime, the company is working on getting its filings back up to date to become SEC reporting again, so its better prepared and more transparent when customers and investors come looking.
We do know the company did at least sell a couple of new PET systems when they issued press releases indicating new system sales in 2018.
As I understand it, the market availability of the RUBY-FILL Rubidium-82 generator, did help increase the use of cardiac PET for myocardial perfusion imaging (MPI) for elderly and obese patients. Rubidium-82 has a short half life and can only be used for completing MPI at rest, and under pharmacologically induced stress. Pharmocologically induced stress is only preffered for obese or immobile that aren't capable of walking on the treadmill to create more natural exercise induced stress.
I think the availability of longer half life, Fluorpiridaz F-18, will be the tipping point where cardiac PET will be preferred over SPECT for all patient populations, and the economics will also then become favorable for small and medium sized cardiology offices to replace their SPECT equipment with cardiac PET machines.....and the Positron Attrius PET is currently the only one that doesn't also include expensive to operate and maintain CT system as well....which isn't needed for PET MPI: https://www.mobilecardiacpet.com/pet-mpi-statistics/
I bought near the lows in 2018 and have been continuing to accumulate into the teens because I believe the company is well positioned to benefit from this coming seachange in cardiac imaging modalities.....and I think there's a good chance of this stock being worth dollars when the market sees the opportunity coming their way as well.
News 
Market Data 
Discover 
